Hopstem Biotechnology
PrivateLast Round
Series C
Aug 10, 2026
Total Funding Raised
$55.5M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Hopstem Biotechnology is a biotechnology company that develops induced pluripotent stem cell (iPSC)-derived therapies for central nervous system disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share, Data as a Service
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Hopstem Biotechnology Comparables
Compare Hopstem Biotechnology with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| XellSmart | 84% | |
| iRegene Therapeutics | 81% | |
| Allife Medicine | 80% |
Hopstem Biotechnology Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Aug 10, 2026 | ||||
| Series B | Oct 31, 2021 | ||||
| Series A Extension | May 28, 2021 | ||||
| Series A Extension | Dec 1, 2020 | ||||
| Series A | Dec 24, 2018 |
Key People
Founding team and executive leadership
Hopstem Biotechnology Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Cybernaut Investment Group | Angel |
| Longmen Capital | Series A Extension |
| Hillhouse Investment | Series B |
| YuanBio Venture Capital | Series B, Angel, Series A Extension |
| Daoyuan Capital | Series A |
| Tasly Capital | Series C |
| Empower Investment | Angel |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 6, 2026
Open roles increased to 10, 2.3x the trailing average.
- Sep 21, 2026
Hiring increased from 0 to 10 roles, representing 100% of headcount.
Recent news
Latest coverage and updates
- receives_financingAug 10, 2026
In Aug '26, Hopstem Biotechnology Inc. completes the first closing of its $29.7M Series C financing in China, backed by Tesly Capital, Haibang Venture, Guangzhou Health Investment and existing shareholder Longmen Capital to support clinical development and commercial-scale manufacturing.
Hopstem Biotechnology Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Hopstem Biotechnology's valuation, stock price, and market status.
Is Hopstem Biotechnology a public or private company?
Hopstem Biotechnology is a private company.
What is the current stock price of Hopstem Biotechnology?
Hopstem Biotechnology is a private company, so its shares have no public market price. Caplight tracks Hopstem Biotechnology's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Hopstem Biotechnology worth (valuation)?
Valuation information for Hopstem Biotechnology is not publicly available.
Can I buy Hopstem Biotechnology stock?
Hopstem Biotechnology shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Hopstem Biotechnology's last funding round?
Hopstem Biotechnology's most recent funding round was Series C on August 10, 2026.
Who are the main investors in Hopstem Biotechnology?
Key investors in Hopstem Biotechnology include Hillhouse Investment, YuanBio Venture Capital, Daoyuan Capital.
Will Hopstem Biotechnology IPO soon?
No public IPO plans have been announced for Hopstem Biotechnology.
How can I track Hopstem Biotechnology secondary market activity?
Caplight tracks bids, offers, and trades in Hopstem Biotechnology's shares on secondary markets.